Senti Bio Sells Its Core Pipeline to Its Biggest Backer for Milestone IOUs — What Is Left for Shareholders?

Shares of Senti Biosciences (SNTI) cratered as much as 47% in two sessions, falling to $0.53 from $1.03 a week earlier, after the company announced it would hand over virtually its entire drug pipeline to an affiliate of its largest shareholder, Celadon Partners. The deal crystallizes what has been a slow-motion cash crisis — and leaves public investors holding a hollowed-out shell with little more than early-stage intellectual property and the hope of distant milestone payments.

• The Company Ran Out of Options, and Nearly Out of Cash. Cash stood at just $8.9 million on March 31, 2026, with $7.5 million burned in a single quarter. Management itself declared "substantial doubt" about its ability to continue operating past Q2 2026. Preliminary figures show only $6.5 million remained as of June 30. A $40 million convertible-note lifeline arranged with Celadon in April included a first tranche of just $10 million, with the remaining $30 million contingent on Celadon's discretion. In short, the company's survival depended entirely on its largest investor's goodwill — and that investor used the leverage to dictate terms.

• Celadon Gets the Crown Jewels; Shareholders Get IOUs. A newly formed private company controlled by Celadon affiliates will acquire the entire pipeline, including the rights to SENTI-202, in exchange for a contingent value right (CVR) — essentially a promise to pay shareholders up to $60 million, but only if future drug milestones are met.

Those milestones include $10 million upon FDA filing acceptance, $20 million upon approval, and $30 million if cumulative sales hit $200 million — benchmarks that could take years to reach, if ever. Meanwhile, analysts had already flagged "severe refinancing and liquidity risks" as recently as May.

• What Remains Is a Tiny, Speculative IP Company. Post-deal, SNTI will stay public but with a "significantly streamlined operating structure," retaining only certain intellectual property and early-stage programs. With the clinical-stage asset gone, there is no near-term revenue catalyst. The market cap has shriveled to roughly $30 million , a fraction of the $47.6 million raised in its last major PIPE round .

• The Insider Dynamic Raises Governance Questions. Celadon is simultaneously the company's largest stockholder and the buyer acquiring substantially all of its business.

The transaction still requires stockholder approval , but Celadon's outsized voting power may make opposition futile. For retail investors, the calculus is bleak: the stock is priced near its 52-week low of $0.77, the CVR payoffs are highly uncertain, and the post-transaction entity has almost no operational substance.